Physician profile
Qaiser Rasheed
NPI 1396702056
$1,625.35
in general payments reported to CMS, 2019-2025
18 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $280 · 2021: $330 · 2022: $86.90 · 2023: $117 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $522.61 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $203.02 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $142.41 | 2019-2023 | |
| Boston Scientific Corporation | $129.31 | 2025 | Farapulse |
| Pfizer INC. | $72.86 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.30 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $57.10 | 2019-2022 | |
| Abbott Laboratories | $52.32 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $45.02 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.31 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $29.06 | 2021-2023 | Verquvo |
| Amgen INC. | $26.87 | 2019-2020 | |
| Medtronic, INC. | $20.33 | 2021 | |
| Resmed Corp | $20.03 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $17.06 | 2023 | Turnpike |
| Impulse Dynamics (USA) INC. | $16.88 | 2025 | Optimizer |
| Esperion Therapeutics, INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qaiser Rasheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.